Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls
Authors:
- Sabrina PaganoniSPSabrina Paganoni
- Merit CudkowiczMCMerit Cudkowicz
- the Pooled Resource Open‐Access ALS Clinical Trials ConsortiumTCthe Pooled Resource Open‐Access ALS Clinical Trials Consortium
Open Access
- 9 October 2023
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 10 (12) , 2297-2304
Abstract
Objective: Sodium phenylbutyrate and taurursodiol (PB and TURSO) was evaluated in amyotrophic lateral sclerosis (ALS) in the CENTAUR trial encompassing randomized placebo‐controlled and open‐label extension phases. On intent‐to‐treat (ITT) survival analysis, median overall survival (OS) was 4.8 months longer and risk of death 36% lower in those originally randomized to an initial 6‐month double‐blind period of PB and TURSO versus placebo. To estimate PB and TURSO treatment effect without placebo‐to‐active crossover, we performed a post hoc survival analysis comparing PB and TURSO‐randomized participants from CENTAUR and a propensity score–matched, PB and TURSO‐naïve external control cohort from the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) database.Methods: Clinical trial control participants from the PRO‐ACT database who met prespecified eligibility criteria were propensity score matched 1:1 with PB and TURSO‐randomized CENTAUR participants using prognostically significant covariates in ALS.Results: Baseline characteristics including propensity score–matched covariates were generally well balanced between CENTAUR PB and TURSO (n = 89) and PRO‐ACT external control (n = 85) groups. Estimated median (IQR) OS was 23.54 (14.56–39.32) months in the CENTAUR PB and TURSO group and 13.15 (9.83–19.20) months in the PRO‐ACT external control group; hazard of death was 52% lower in the former group (hazard ratio, 0.48; 95% CI, 0.31–0.72; p = 0.00048).Interpretation: This analysis suggests potentially greater survival benefit with PB and TURSO in ALS without placebo‐to‐active crossover than seen on ITT analysis in CENTAUR. Analyses using well‐matched external controls may provide additional context for evaluating survival effects in future ALS trials.Keywords
Funding Information
- Amyotrophic Lateral Sclerosis Association
This publication has 22 references indexed in Scilit:
- A Review of Propensity-Score Methods and Their Use in Cardiovascular ResearchCanadian Journal of Cardiology, 2016
- Rate of disease progression: a prognostic biomarker in ALSJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithmJournal of Neurology, 2015
- The PRO-ACT databaseNeurology, 2014
- Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic EvaluationValue in Health, 2014
- Methods for Adjusting for Bias Due to Crossover in Oncology TrialsPharmacoEconomics, 2014
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2000
- The combination of randomized and historical controls in clinical trialsJournal of Chronic Diseases, 1976